1-2 of 2
Gerben Zwezerijnen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Improved Efficacy with Response- and MRD-Guided Ibrutinib-Obinutuzumab (IO) Intensification after Ibrutinib-Venetoclax (IV) in First Line Chronic Lymphocytic Leukemia (CLL) Patients: Primary Analysis of the HOVON 158/Next STEP Phase 2 Trial

Mark-David Levin, Sabina Kersting, Julie Dubois, Bronno van der Holt, Caspar da Cunha-Bang, Doreen te Raa, Cecile Idink, Fransien De Boer, Jolanda Droogendijk, Koen de Heer, Leonie van der Burg, Marten R. Nijziel, Lidwine Tick, Henriettte Levenga, Matthijs Silbermann, Inge Ludwig, Aart Beeker, Mar Bellido, Anne-Marie Van Der Kevie-Kersemaekers, Clemens Mellink, Ine Meulendijks, Sjoerd Zoun-van den Dool, Martine Abrahamse-Testroote, Gerben Zwezerijnen, Carsten Utoft Niemann, Arnon P. Kater
Journal: Blood
Blood (2024) 144 (Supplement 1): 1013.
https://doi.org/10.1182/blood-2024-207452
Published: 2024
Journal Articles

Improved Risk Prediction in DLBCL By Combining Clinical and PET Features with Interim PET Assessment

Christine Hanoun, Martijn Heymans, Sanne Wiegers, Annelies Bes, Ulrich Duehrsen, Andreas Huettmann, Lars Kurch, Sally F Barrington, George Mikhaeel, Pieternella Lugtenburg, Luca Ceriani, Emanuele Zucca, Tamas Gyorke, Sandor Czibor, Gerben Zwezerijnen, Ronald Boellaard, Josée M. Zijlstra, Corinne Eertink
Journal: Blood
Blood (2023) 142 (Supplement 1): 1740.
https://doi.org/10.1182/blood-2023-190277
Published: 2023